In postmenopausal women with more severe low bone mass (T-score ≤-2.8), serum irisin was not affected by 3 months of teriparatide compared with age-matched controls.
In plain wordsIn women with severe low bone mass, 3 months of teriparatide did not change blood irisin levels compared with age-matched controls.
- Peptide
- Teriparatide (PTH 1-34)
- Outcome
- No significant changeSerum irisin
- Study
n = 50
- Comparator
- Age-matched controls
- Outcome group
- Bone and joint · Musculoskeletal
- Studied dose
- Dose not stated · 3 monthsAs given in this study (human).
Source sentences
Serum irisin levels were not different between women with or without low bone mass and were not affected by either Dmab or TPTD treatment for 3 months.
1 context sentence(design, population, supporting numbers)
(b) women with more severe disease (LS or FN BMD T-score ≤-2.8) and their age-matched controls at the above-mentioned time points after teriparatide (TPTD) initiation (TPTD group, n = 25; TPTD control group, n = 25).